Abstracts


A-25. Schatzberg AF. Discriminacion biologica entre panico y depresion. Resumen del Simposio Conjunto entre el Instituto Mexicano de Psiquiatria y el Hospital McLean, Salud Mental, 1983; 6:68.

A-26. Schatzberg AF. El mapeo de la actividad electrica del cerebra (BEAM) de enfermos deprimidos. Resumen del Simposio Conjunto entre el Instituto Mexicano de Psiquitria y el Hospital McLean, Salud Mental, 1983; 6:72.


A-146. Schatzberg AF. Recent advances in refractory mood disorders. 48th Institute on Psychiatric Services, 1996:70.


A-177. Schatzberg AF, Cantillon M. Antidepressant early response and remission of venlafaxine (Effexor) and fluoxetine (Prozac) in geriatric outpatients. 22nd CINP Congress. 2000:S191.


A-229. Schatzberg AF. Chronic depression: medication (Nefazodone) or psychotherapy (CBASP) is effective when the other is not. Abstracts of the NCDEU, 2006.


A-244. Schatzberg AF, Belanoff J. Glucocorticoid receptor antagonists as a novel treatment option in psychotic depression. Annual Meeting, XXVI Congress of the CINP, 2008:S-20.03.


Schatzberg AF. Mineralocorticoid receptor function in depression: new findings using neuroimaging and cognitive testing. Abstracts of the 24th ECNP Congress, 2011:S.16.05.


Original Reports (Journals)


81. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. JAMA 1996; 276(4):313-318.


301. Schatzberg AF. Anna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the
hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major

RM, et al. fMRI Activation During Executive Function Predicts Response to Cognitive
Behavioral Therapy in Older, Depressed Adults. Am J Ger Psychiatry 2015; 23(1): 13-
22.

303. Bunney BG, Li JZ, Walsh DM, Stein R, Vawter MP, Cartagena P, Barchas JD,
Schatzberg AF, et al. Circadian dysregulation of clock genes: clues to rapid treatments

304. Day CV, Rush A John, Harris AW, Boyce PM, Rekshan W, Etkin A, DeBattista
C, Schatzberg AF, et al. Impairment and distress patterns distinguishing the melancholic

A Cognitive-Emotional Biomarker for Predicting Remission with Antidepressant
Medications: A Report from the iSPOT-D Trial. Neuropsychopharmacology 2015;

306. Oathes DJ, Patenaude B, Schatzberg AF, Etkin A. Neurobiological signatures of
anxiety and depression in resting-state functional magnetic resonance imaging. Biol

307. Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the
development of novel therapeutics for mood disorders? Neuropsychopharmacology

C, Schatzberg AF, et al. The international Study to Predict Optimized Treatment in
Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J

O'Hara R, Schatzberg AF. Decreased hypothalamic functional connectivity with
subgenual cortex in psychotic major depression. Neuropsychopharmacology 2015;

310. Thompson DG, Kesler SR, Sudheimer K, Mehta KM, Thompson LW, Marquett
RM, Holland JM, Reiser R, Rasgon N, Schatzberg AF, O'Hara RM. fMRI activation
during executive function predicts response to cognitive behavioral therapy in older,

311. Schatzberg AF. The chicken and egg of anxiety and depression. Epidemiology and
Epidemiology and Psychiatric Sciences 2015; 24: 210-226.

Original Reports (Proceedings)


Letters to the Editor and Invited Editorials


**Reviews (Chapters)**


6. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Herzog JM, Gudeman JE, Cole JO, Rohde WA, LaBrie RA. Biochemical discrimination of subgroups of affective and


Books and Monographs


Non-Print Materials


8. Schatzberg AF. Moderator, Am College of Psychiatrists Psychiatry Update - "Update on anxiolytic medications" (audiocassette program), 1986.


Alan F. Schatzberg
December 31, 2015